Latin America health disparities R01 eligibility Guide
Updated 6 official sources
Quick Answer: PAR-25-342 no longer accepts applications. NIMHD expired it "effective immediately" on June 3, 2026 in NOT-MD-26-001 (opens in a new tab), almost a year before its original May 8, 2027 expiration date, and the notice names no replacement.
Full answer and how we checked it
Use this page as a reference for what the NOFO asked for (8 checks: clinical trial status, NCD focus, disparity outcome, Latin America or U.S. Hispanic/Latino fit, intervention design, partnership evidence, foreign-component rules, and 5-year scope), then look for a current route on NIMHD's active funding opportunities list (opens in a new tab).
Who this is for: This guide is for health disparities researchers, Latin America collaborators, U.S. Hispanic/Latino health teams, clinical-trial offices, and sponsored-research staff who planned around PAR-25-342 and now need to judge what carries over to another NIH route.
Data note: This guide uses NIH PAR-25-342 (opens in a new tab), NIMHD health disparities research framework (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 358157 (opens in a new tab), and the NIMHD early-expiration notice NOT-MD-26-001 (opens in a new tab), rechecked on October 11, 2026.
In this guide
- October 2026 Status Check
- 8 PAR-25-342 Eligibility Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This Proposal Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 28-Day R01 Readiness Plan
- 5 Real-World Fit Tests For PAR-25-342 Teams
- 5 Final R01 Review Questions
- 7 Route Checks (Updated October 2026)
- Sources
Quick Facts
- Agency
- HHS
- Deadline on record
- May 7, 2027 (notice closed)
- Status
- Closed
Assistance Listing 93.313: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.313, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 6
- Avg Award (whole listing)
- $2,220,685
- Median Award (whole listing)
- $2,735,186
Data last verified: May 26, 2026
According to NIH PAR-25-342 (opens in a new tab), the NOFO supported clinical, health services, or community-based intervention research addressing health and healthcare disparities related to high-burden non-communicable and chronic diseases in Latin America and among U.S. Hispanics/Latinos.
The key question was whether the project tested an intervention that could reduce disparities. Documenting disease burden or describing inequity wasn't enough. That test still matters, because most NIH disparities routes ask the same question.
Use this guide with the live Latin America health disparities R01 program record, NIH grants complete guide, what is a NOFO, NIH Clinical Center U01 guide, NHLBI early phase R61/R33 guide, and the Grantsights grant database.
October 2026 Status Check
PAR-25-342 is closed. On June 3, 2026, NIMHD published NOT-MD-26-001 (opens in a new tab), which says the NOFO "has expired effective immediately" and that no further applications will be accepted. The NOFO page (opens in a new tab) now lists June 3, 2026 as its expiration date (original date: May 8, 2027). The June 5, 2026 new-application date and July 5, 2026 resubmission date never happened for this NOFO. Grantsights checked the NOFO page against the notice on October 11, 2026, and neither one names a successor.
| Source fact | October 2026 answer |
|---|---|
| Status | Expired June 3, 2026 (NOT-MD-26-001) |
| Funding number | PAR-25-342 |
| Activity | R01 Research Project Grant |
| Clinical trial status | Required |
| Budget rule | Not limited, but tied to actual project need |
| Project period | Up to 5 years |
| Direct foreign applicant | Not eligible |
| Foreign component | Allowed |
The rest of the table describes the NOFO as written. If you had a draft in progress, keep the science but don't submit against this number. A team with a Latin America NCD disparities trial should check NIMHD's active funding opportunities (opens in a new tab) and the NIH Guide for a current route, and should email the NIMHD program contact before reworking aims. While it was open, NIH expected an intervention that addresses NCD health or healthcare disparities, includes Latin America-based key personnel, and avoids descriptive-only disparity studies.
8 PAR-25-342 Eligibility Checks
Use these 8 stop checks to test a draft that was built for PAR-25-342 before you move it to another NOFO. If the work only describes disparities, pause.
| Stop check | Strong R01 signal | Red flag |
|---|---|---|
| Clinical trial | NIH-defined trial is central | Trial status is unclear |
| NCD focus | High-burden non-communicable disease is named | Topic is outside NCD scope |
| Disparity outcome | Intervention addresses health or healthcare disparity | Outcome is only clinical improvement |
| Population fit | Latin America or U.S. Hispanic/Latino population is central | Population is incidental |
| Intervention | Clinical, health services, or community-based intervention is tested | Only surveys or qualitative work |
| Partnership | Cross-site roles and local context are clear | Partnership is extractive or thin |
| Foreign rules | Applicant and foreign components match NIH rules | Non-U.S. applicant eligibility is assumed |
| Scope | Budget and period fit up to 5 years | Project is too broad or unfocused |
According to NIH, PAR-25-342 required clinical trials, allowed project periods up to 5 years, and didn't limit budgets except that they had to reflect actual project needs.
5 Source Facts Applicants Should Know
According to NIH, the NOFO excluded studies that only identify, describe, or explain disparities, and studies focused on improving health outcomes without trying to reduce disparities.
This route wasn't for broad global health work. It was for intervention research tied to NCD disparities.
| Fact | Source-backed read |
|---|---|
| NOFO | PAR-25-342 |
| Activity | R01 |
| Status | Expired June 3, 2026 |
| Clinical trial | Required |
| Project period | Up to 5 years |
| Main institute | NIMHD, with NINR and ORWH participation |
The March 31, 2025 notice said the opportunity was updated to align with agency priorities, and the June 3, 2026 early expiration followed about 14 months later. That history is a red flag for any team that plans a long drafting cycle around one NOFO: recheck the NIH Guide for notices right before submission.
What NIH Doesn't Tell You
Answer 5 practical questions. First, a strong disparities paper is not automatically a strong PAR-25-342 proposal. The application must test an intervention.
Second, the intervention should target disparity mechanisms, not only outcomes. If a diabetes intervention improves A1c equally for everyone but does not address access, quality, trust, structural barriers, delivery, or context, the disparities argument may be weak.
Third, the Latin America and U.S. Hispanic/Latino framing needs care. The proposal should not treat populations as interchangeable. It should explain country context, language, health system, migration, culture, implementation setting, and comparison logic.
Fourth, foreign-component rules need early review. Under this NOFO, foreign organizations weren't eligible to apply, but foreign components were allowed. A replacement route may set different rules.
Fifth, NIH can end a NOFO early with a one-paragraph notice. PAR-25-342 had a published expiration date of May 8, 2027 and closed on June 3, 2026.
6 Evidence Assets That Make This Proposal Stronger
These 6 evidence assets carry over to most NIH disparities trial routes. Asset 1 is the disparity-mechanism map. Name the NCD, population, setting, inequity, mechanism, and proposed intervention target.
Asset 2 is the clinical-trial determination memo. NIH clinical-trial status drives forms, review, data and safety monitoring, and milestones.
Asset 3 is the intervention evidence table. Summarize prior evidence, why adaptation is needed, what changes, and how the intervention targets disparity.
Asset 4 is the partnership and governance plan. Local partners should have defined authority in recruitment, implementation, interpretation, and dissemination.
Asset 5 is the foreign-component and applicant-eligibility memo. Confirm the applicant entity, subawards, consultants, and site roles before the budget is built.
Asset 6 is the route memo. Since PAR-25-342 has expired, compare current parent R01 trial routes, NIMHD routes, implementation science routes, NHLBI routes, NCI routes, and foundation funders.
5 Route Choices Before Drafting
PAR-25-342 is no longer one of the options, so compare the remaining routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-342 | Closed June 3, 2026 | Don't submit; no applications accepted |
| Parent R01 clinical trial route | Topic is trial-ready but not Latin America disparities focused | General route may fit |
| NIMHD or NINR route | Disparity method or nursing research dominates | Institute route may fit |
| NHLBI or NCI trial route | Heart, lung, blood, sleep, or cancer product development dominates | Disease route may fit |
| Foundation or local funder | Service delivery or local program work dominates | Federal R01 may be too research-heavy |
Warning: don't pick any R01 route because a study happens in Latin America. Pick it because the intervention directly addresses the disparity mechanisms that NOFO names.
6 Bad-Fit Signals
First, the study is exclusively qualitative. Second, it only describes disparities. Third, the intervention is not modified for the population or setting.
Fourth, the disease focus is outside high-burden NCDs. Fifth, the applicant assumes a non-U.S. entity can submit directly. Sixth, the trial status is underdeveloped.
Fit problems for disparities NOFOs often show up in the aims. If Aim 1 maps a disparity and Aim 2 interviews participants but no aim tests an intervention, the fit is weak.
28-Day R01 Readiness Plan
Days 1 through 4 should write the disparity-mechanism map and route comparison. Days 5 through 9 should confirm clinical-trial status, applicant eligibility, and foreign-component structure.
Days 10 through 15 should build the intervention evidence table, outcome hierarchy, recruitment plan, and data and safety monitoring outline. Days 16 through 21 should draft the research strategy, partnership plan, and budget. Days 22 through 28 should check NIH policy notices, human subjects forms, and source freshness. Start the plan only after you've found an open NOFO, since PAR-25-342 can't receive applications.
Don't draft around a vague disparity statement. The intervention has to show how the disparity changes.
5 Real-World Fit Tests For PAR-25-342 Teams
These 5 hypothetical examples show how the NOFO drew its lines. A U.S. university partnering with clinics in Peru to test a hypertension care intervention for low-income adults would have fit if the study measures disparity reduction, not only blood-pressure change. According to NIH, the NOFO was for clinical, health services, or community-based interventions that address disparities linked to high-burden NCDs.
A diabetes registry study in Mexico that only describes differences in outcomes probably wasn't enough. NIH said studies focused only on identifying, describing, or explaining disparities weren't supported under this NOFO.
A cancer screening project serving U.S. Hispanic/Latino patients could fit if it tested delivery changes that address access, quality, language, trust, or system barriers. It got weaker if the intervention was copied without adaptation and the disparity mechanism is not named.
A chronic lung disease project in Chile needed a U.S. applicant with a foreign component, not a foreign organization as the direct applicant. According to NIH, non-U.S. entities weren't eligible to apply, while foreign components were allowed. In practice, that pointed to a U.S. institution submitting the application and describing the Chilean site as a foreign component of the project.
A community health worker trial in Colombia should map trial responsibilities, data and safety monitoring, local governance, and implementation context before drafting aims. Teams can lose months by treating partnership governance as an attachment issue rather than a science issue.
5 Final R01 Review Questions
Ask 5 review questions of any draft that started on PAR-25-342. First, does the new NOFO you're targeting require a clinical trial, and does the first screen say so? Second, does it make disparity reduction different from general outcome improvement? Third, does it name Latin America and U.S. Hispanic/Latino populations without treating them as one group?
Fourth, does it follow the new NOFO's foreign-organization and foreign-component rules? Fifth, does it name the disease, country, and method clearly enough that a reviewer can see what the intervention changes?
7 Route Checks (Updated October 2026)
Checked against official source 1 (opens in a new tab), official source 2 (opens in a new tab), official source 3 (opens in a new tab), official source 4 (opens in a new tab), and NOT-MD-26-001 (opens in a new tab) on October 11, 2026.
| Check | What to confirm |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for Latin America health disparities R01 eligibility. |
| Source status | PAR-25-342 expired June 3, 2026. Confirm the replacement NOFO is open and has a future due date. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NIH or federal route. |
| Review criteria | PAR-25-342 used NIH's simplified review framework: Factor 1 Importance of the Research, Factor 2 Rigor and Feasibility, Factor 3 Expertise and Resources. |
| Next action | Decide whether to draft, ask a program contact, or redirect. |
Final public checklist
- Confirm whether R01 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
- NIH PAR-25-342 (opens in a new tab)
- NOT-MD-26-001: early expiration of PAR-25-342 (opens in a new tab)
- NIMHD active funding opportunities (opens in a new tab)
- NIMHD health disparities research framework (opens in a new tab)
- NIH clinical trials policy (opens in a new tab)
- Grants.gov listing 358157 (opens in a new tab)
Largest awards active in FY2024
One row per recipient, its largest award | 6 Assistance Listing records | Avg: $2.2M
Augusta University Research Institute, Inc
GA
University of North Carolina at Chapel Hill
NC
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open Latin America R01 record
Check PAR-25-342, June 5 2026 timing, clinical-trial-required status, NCD disparity scope, and foreign rules.
Compare clinical collaboration route
Use when the project includes clinical-site operations or NIH resource collaboration rather than NCD disparity intervention research.
Compare early-phase trial route
Use when heart, lung, blood, or sleep disease development fit is stronger than the PAR-25-342 disparity route.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
Is PAR-25-342 still accepting applications?
No. NIMHD expired PAR-25-342 effective immediately on June 3, 2026 (NOT-MD-26-001), well before its original May 8, 2027 expiration date. The notice says no further applications will be accepted and names no replacement, so check NIMHD's active funding opportunities list for current routes.
What did PAR-25-342 support?
It supported clinical, health services, or community-based intervention research addressing health and healthcare disparities for non-communicable diseases in Latin America and among U.S. Hispanics/Latinos.
Is a clinical trial required?
Yes. While it was open, PAR-25-342 only accepted applications that proposed clinical trials.
What project period is allowed?
The NOFO set a maximum project period of 5 years.
Are foreign organizations eligible?
No. The NOFO said non-U.S. entities and non-U.S. components of U.S. organizations weren't eligible, but foreign components were allowed. Check any replacement NOFO for its own foreign rules.
What kinds of studies did this NOFO not fit?
It didn't fit when the study is exclusively qualitative, only describes disparities, lacks an intervention, or is not focused on high-burden non-communicable disease.
Last updated October 12, 2026. Corrected October 11, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
NIH Grants 2026: R01, K Awards, R21, R35, SBIR
Compare NIH R01, K awards, R21, R03, R35, SBIR/STTR, success rates, deadlines, and program pages before choosing a route.
NIH BRG R01 Guide 2026: Eligibility
NIH BRG R01 guide for 2026: eligibility, $500K direct-cost cap, clinical-trial status, team fit, R01 route checks, and fit.
NIH Clinical Center U01 Eligibility Guide
NIH Clinical Center U01 guide: 8 checks for PAR-26-116, intramural collaboration, Clinical Center use, $500K direct-cost cap, and LOS prep.
NIH Emergency Competitive Revision Guide
PA-24-201 guide: NIH emergency competitive revision eligibility, active parent award rule, Emergency NOSI requirement, disaster basis, and route checks.
NIH K24 Midcareer Investigator Award Guide
NIH K24 midcareer investigator award eligibility guide for PA-24-188, 25% to 50% effort, mentoring proof, trial limits, and route choice.
NIH NextTech R18 Guide 2026: Eligibility
NIH NextTech R18 guide for 2026: eligibility, $6M program funding, BRAIN and HEAL fit, first-in-human readiness, and trial limits.